Clinical Trials Logo

Supratentorial Neoplasms clinical trials

View clinical trials related to Supratentorial Neoplasms.

Filter by:
  • Active, not recruiting  
  • Page 1

NCT ID: NCT04490954 Active, not recruiting - Brain Tumor Clinical Trials

The Accuracy of Brain Biological Electrical Impedance Tomography Screen for Supratentorial Tumors

ABST
Start date: August 1, 2019
Phase: N/A
Study type: Interventional

Compared with MRI or CT, brain biological electrical impedance tomography were performed on patients with supratentorial tumors and healthy people . The AUC (area under the curve) of ROC, which is associated with the increased maximum and the difference between left and right equilibrium of impedance value, is calculated. The specificity of brain biological electrical impedance tomography in screening supratentorial tumors are evaluated. To compare the changes of parameters detected by brain biological electrical impedance tomography, the enrolled brain tumor patients with cerebral edema were paired with themselves and intravenous infusion of mannitol so that the sensitivity of this device in monitoring cerebral edema can be evaluated.

NCT ID: NCT00102648 Active, not recruiting - Clinical trials for Recurrent Glioblastoma

Lonafarnib and Temozolomide in Treating Patients With Glioblastoma Multiforme That Is Recurrent or Did Not Respond to Previous Treatment With Temozolomide

Start date: December 21, 2004
Phase: Phase 1
Study type: Interventional

This phase I trial studies the side effects and best dose of lonafarnib when given together with temozolomide and to see how well they work in treating patients with glioblastoma multiforme that is has come back or did not respond to previous treatment with temozolomide. Lonafarnib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Drugs used in chemotherapy, such as temozolomide, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving lonafarnib together with temozolomide may kill more tumor cells.